Combination strategies to optimize the efficacy of chimeric antigen receptor T cell therapy in haematological malignancies

被引：18

作者：

Xiao, Xinyi ^{[1
]}

Wang, Yazhuo ^{[2
]}

Zou, Zhengbang ^{[1
]}

Yang, Yufei ^{[1
]}

Wang, Xinyu ^{[1
]}

Xin, Xin ^{[1
]}

Tu, Sanfang ^{[3
]}

Li, Yuhua ^{[3
,4
]}

机构：

[1] Southern Med Univ, Zhujiang Hosp, Sch Clin Med 2, Guangzhou, Peoples R China

[2] Southern Med Univ, Sch Rehabil Sci, Guangzhou, Peoples R China

[3] Southern Med Univ, Zhujiang Hosp, Dept Haematol, Guangzhou, Peoples R China

[4] Guangzhou Regenerat Med & Hlth Guangdong Lab, Bioland Lab, Guangzhou, Peoples R China

来源：

FRONTIERS IN IMMUNOLOGY | 2022年 / 13卷

基金：

中国国家自然科学基金;

关键词：

CAR T cell; resistance; relapse; combination therapy; chemotherapy; radiotherapy; haematological stem cell transplantation; targeted therapy; ACUTE LYMPHOBLASTIC-LEUKEMIA; MEMORY STEM-CELLS; B-CELL; MULTIPLE-MYELOMA; AXICABTAGENE CILOLEUCEL; EX-VIVO; EXPANSION; SAFETY; APOPTOSIS; IBRUTINIB;

D O I：

10.3389/fimmu.2022.954235

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Chimeric antigen receptor (CAR) T cell therapy has revolutionized the therapeutic landscape of haematological malignancies. However, resistance and relapse remain prominent limitations, and they are related to the limited persistence and efficacy of CAR T cells, downregulation or loss of tumour antigens, intrinsic resistance of tumours to death signalling, and immune suppressive microenvironment. Rational combined modality treatments are regarded as a promising strategy to further unlock the antitumor potential of CAR T cell therapy, which can be applied before CAR T cell infusion as a conditioning regimen or in ex vivo culture settings as well as concomitant with or after CAR T cell infusion. In this review, we summarize the combinatorial strategies, including chemotherapy, radiotherapy, haematopoietic stem cell transplantation, targeted therapies and other immunotherapies, in an effort to further enhance the effectiveness of this impressive therapy and benefit more patients.

引用

页数：22

共 195 条

[51] Unmanipulated haploidentical hematopoietic stem cell transplantation is an excellent option for children and young adult relapsed/refractory Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia after CAR-T-cell therapy [J].

Hu, Guan-Hua ;

Zhao, Xiang-Yu ;

Zuo, Ying-Xi ;

Chang, Ying-Jun ;

Suo, Pan ;

Wu, Jun ;

Jia, Yue-Ping ;

Lu, Ai-Dong ;

Li, Ying-Chun ;

Wang, Yu ;

Jiao, Shun-Chang ;

Zhang, Long-Ji ;

Kong, Jun ;

Yan, Chen-Hua ;

Xu, Lan-Ping ;

Zhang, Xiao-Hui ;

Liu, Kai-Yan ;

Cheng, Yi-Fei ;

Wang, Yu ;

Zhang, Le-Ping ;

Huang, Xiao-Jun .

LEUKEMIA, 2021, 35 (11) :3092-3100

[52] Auto Hematopoietic Stem Cell Transplantation Combined with Another Target Humanized CART Cells for Refractory/Relapsed B-Cell NonHodgkin Lymphoma after Failure of Murinized CD19-CAR-T Therapy [J].

Hu, Kai ;

Yang, Fan ;

Liu, Rui ;

Xu, Teng ;

Zheng, Peihao ;

Feng, Shaomei ;

Guo, Yuelu ;

Shi, Hui ;

Deng, Biping ;

Ke, Xiaoyan ;

Wu, Tong .

BLOOD, 2021, 138

[53] Activation-induced cell death in CAR-T cell therapy [J].

Huan, Tian ;

Chen, Dongfeng ;

Liu, Guodong ;

Zhang, Hailing ;

Wang, Xiaoyan ;

Wu, Zhi ;

Wu, Yan ;

Xu, Qinggang ;

Yu, Feng .

HUMAN CELL, 2022, 35 (02) :441-447

[54] Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial [J].

Hutchings, Martin ;

Morschhauser, Franck ;

Iacoboni, Gloria ;

Carlo-Stella, Carmelo ;

Offner, Fritz C. ;

Sureda, Anna ;

Salles, Gilles ;

Martinez-Lopez, Joaquin ;

Crump, Michael ;

Thomas, Denise N. ;

Morcos, Peter N. ;

Ferlini, Cristiano ;

Broeske, Ann-Marie E. ;

Belousov, Anton ;

Bacac, Marina ;

Dimier, Natalie ;

Carlile, David J. ;

Lundberg, Linda ;

Perez-Callejo, David ;

Umana, Pablo ;

Moore, Tom ;

Weisser, Martin ;

Dickinson, Michael J. .

JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (18) :1959-+

[55] Real-world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B-cell lymphoma [J].

Iacoboni, Gloria ;

Villacampa, Guillermo ;

Martinez-Cibrian, Nuria ;

Bailen, Rebeca ;

Lopez Corral, Lucia ;

Sanchez, Jose M. ;

Guerreiro, Manuel ;

Carolina Caballero, Ana ;

Mussetti, Alberto ;

Sancho, Juan-Manuel ;

Hernani, Rafael ;

Abrisqueta, Pau ;

Solano, Carlos ;

Sureda, Anna ;

Briones, Javier ;

Martin Garcia-Sancho, Alejandro ;

Kwon, Mi ;

Luis Reguera-Ortega, Juan ;

Barba, Pere .

CANCER MEDICINE, 2021, 10 (10) :3214-3223

[56] Sequential Single-Cell Transcriptional and Protein Marker Profiling Reveals TIGIT as a Marker of CD19 CAR-T Cell Dysfunction in Patients with Non-Hodgkin Lymphoma [J].

Jackson, Zachary ;

Hong, Changjin ;

Schauner, Robert ;

Dropulic, Boro ;

Caimi, Paolo F. ;

de Lima, Marcos ;

Giraudo, Maria Florencia ;

Gupta, Kalpana ;

Reese, Jane S. ;

Hwang, Tae Hyun ;

Wald, David N. .

CANCER DISCOVERY, 2022, 12 (08) :1886-1903

[57] Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial [J].

Jacobson, Caron A. ;

Chavez, Julio C. ;

Sehgal, Alison R. ;

William, Basem M. ;

Munoz, Javier ;

Salles, Gilles ;

Munshi, Pashna N. ;

Casulo, Carla ;

Maloney, David G. ;

de Vos, Sven ;

Reshef, Ran ;

Leslie, Lori A. ;

Yakoub-Agha, Ibrahim ;

Oluwole, Olalekan O. ;

Fung, Henry Chi Hang ;

Rosenblatt, Joseph ;

Rossi, John M. ;

Goyal, Lovely ;

Plaks, Vicki ;

Yang, Yin ;

Vezan, Remus ;

Avanzi, Mauro P. ;

Neelapu, Sattva S. .

LANCET ONCOLOGY, 2022, 23 (01) :91-103

[58] Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity [J].

Jacobson, Caron A. ;

Hunter, Bradley D. ;

Redd, Robert ;

Rodig, Scott J. ;

Chen, Pei-Hsuan ;

Wright, Kyle ;

Lipschitz, Mikel ;

Ritz, Jerome ;

Kamihara, Yusuke ;

Armand, Philippe ;

Nikiforow, Sarah ;

Rogalski, Michael ;

Maakaron, Joseph ;

Jaglowski, Samantha ;

Maus, Marcela V. ;

Chen, Yi-Bin ;

Abramson, Jeremy S. ;

Kline, Justin ;

Budde, Elizabeth ;

Herrera, Alex ;

Mei, Matthew ;

Cohen, Jonathon B. ;

Smith, Stephen D. ;

Maloney, David G. ;

Gopal, Ajay K. ;

Frigault, Matthew J. ;

Acharya, Utkarsh H. .

JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (27) :3095-+

[59] End of Phase 1 Results from Zuma-6: Axicabtagene Ciloleucel (Axi-Cel) in Combination with Atezolizumab for the Treatment of Patients with Refractory Diffuse Large B Cell Lymphoma [J].

Jacobson, Caron A. ;

Locke, Frederick L. ;

Miklos, David B. ;

Herrera, Alex F. ;

Westin, Jason R. ;

Lee, Jennifer ;

Rossi, John M. ;

Zheng, Lianqing ;

Avanzi, Mauro P. ;

Roberts, Zachary J. ;

Sun, Jennifer .

BLOOD, 2018, 132

[60] Consolidative allogeneic hematopoietic stem cell transplantation after chimeric antigen receptor T-cell therapy for relapsed/refractory B-cell acute lymphoblastic leukemia: who? When? Why? [J].

Jiang, Huiwen ;

Hu, Yu ;

Mei, Heng .

BIOMARKER RESEARCH, 2020, 8 (01)

← 1 2 3 4 5 6 7 8 9 10 →